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There are three members of the β -adrenoceptor family all of which are primarily coupled to Gs-proteins. Recent studies using the huge range of β -ligands now available have given remarkable new insights into their pharmacology. β 1-adrenoceptors exist in at least two active conformations while β 2-adrenoceptors are able to induce signalling via different agonist-induced receptor conformational states and their affinity for antagonists can be altered by highly efficacious agonists. This study therefore examined the pharmacology of the human β 3-adrenoceptor stably expressed in CHO cells. Several compounds previously described as β -antagonists have agonist properties at the β 3-adrenoceptor. Antagonist affinity measurements varied at the β 3-adrenoceptor in a similar manner to those observed at human β 1-adrenoceptors and unlike those seen at β 2-adrenoceptors. Some ligands e.g. fenoterol and cimaterol were more readily inhibited by all antagonists whilst other ligands (e.g.
alprenolol and SR 59230A) stimulated responses that were more resistant to antagonism. Alprenolol inhibited fenoterol induced β 3-adrenoceptor responses whilst acting as an agonist at higher concentrations. This is highly suggestive of two active conformational states of the β 3-adrenoceptor. ZD 7114 stimulated a two-component response of which the first component was more readily antagonised than the second.
Taken together, these experiments suggest that the human β 3-adrenoceptor exists in at least two different agonist conformations with a similar high and low-affinity pharmacology analogous to, if not as pronounced as, the β 1-adrenoceptor. Both conformations are present in living cells and can be distinguished by their pharmacological characteristics. In this respect, the human β 3-adrenoceptor appears similar to the human β 1-adrenoceptor.
Introduction
There are three members of the β -adrenoceptor family (β1, β 2 and β 3-adrenoceptors)
which are all G-protein coupled receptors primarily coupled to Gs-proteins and have been studied extensively. However, recent studies using the huge range of β -ligands now available have given remarkable new insights into their pharmacology.
The β 1-adrenoceptor is now considered to exist in at least two active conformations and although the structural nature of these two conformations or states remains unknown, they have different pharmacological properties (Granneman, 2001; Molenaar, 2003; Arch, 2004) . All reports so far have described ligands as having higher affinity for the classical catecholamine-conformation than the secondary (lowaffinity, formally the putative β 4-adrenoceptor) conformation. Furthermore, measurements of antagonist affinity revealed that agonist responses occurring via the catecholamine-conformation are readily inhibited by classical antagonists whereas those occurring via the secondary low-affinity state are relatively resistant to antagonism (Konkar et al., 2000; Lowe et al, 2002; Baker et al., 2003a; Baker, 2005a) . Finally, the efficacy of ligands, including many drugs previously described as "β-blockers" differs between the two states: some ligands are antagonists at both conformations; others have agonist action at the secondary-conformation whilst behaving as antagonists of the catecholamine-state; some appear to purely activate the catecholamine-state whilst others clearly activate both conformations (Konkar et al., 2000; Baker et al., 2003a) .
The β 2-adrenoceptor has not to date been demonstrated to have two active conformations with distinct ligand affinity and efficacy differences akin to the β 1-adrenoceptor. However, recent studies have demonstrated that ligands are able to induce different conformational states of the receptor that activate different intracellular signalling cascades. Whilst many agonists and inverse agonists have been described that either increase or decrease intracellular cAMP respectively (Jasper et al., 1990; Chidiac et al., 1994; Bond et al., 1995; Baker et al., 2003b) , other ligands have been described that simultaneously act as inverse agonists of one pathway (β2-Gs-cAMP) whilst having agonist activity via a second separate pathway in the same cells (β2-p42/44 MAP Kinase pathway; Azzi et al., 2003; This article has not been copyedited and formatted. The final version may differ from this version. 2003b). In different tissues, the β 2-adrenoceptor has also been shown to couple to Giproteins under certain conditions (e.g. Daaka et al., 1997; Brown and Harding 1992; Hassledine et al., 2003) . Furthermore studies of antagonist affinity have revealed that the affinity of an antagonist for the receptor changes in a time-dependent, phosphorylation-dependent manner, a property not shared by the β 1-adrenoceptor (Baker et al., 2003c; Baker 2005a ).
The expression pattern of the β 3-adrenoceptor is somewhat contentious but reports include expression in gut, gall bladder, brain, urogenital tissue, skeletal muscle and the heart, however its primary function (at least in rodents) appears to be in thermogenesis as a consequence of its expression in adipose tissue (Strosberg 1997; Gauthier et al., 2000; Arch 2001 properties at the β 3-adrenoceptor (Blin et al., 1993; Gerhardt et al., 1999; Hutchinson et al., 2005) . There are however important differences between rodent and human β 3-adrenoceptors in their physiology and pharmacological function in both adipose tissue and the heart (Strosberg 1997; Gauthier et al., 2000; Arch 2001 ). The β 3-adrenoceptor has also be shown to couple to Gi-proteins in certain tissues/conditions (rodent, Chaudhry et al., 1994; Hutchinson et al., 2002; human, Gauthier et al., 1996) and a recent study of mouse β 3-adrenoceptor function has revealed the existence of different downstream signalling cascades (similar to that of the human β 2-adrenoceptor) that are targeted by different ligands (Hutchinson et al., 2005) . Finally, studies of adenylyl cyclase and membrane binding have revealed different potencies for ligands leading to the suggestion of a two-state model of human β 3-adrenoceptor (not dissimilar to that of the human β 1-adrenoceptor), but with one state that exists in membranes and a second state that predominates in whole cells (Arch 2002) .
The aim of this study was to systematically examine the pharmacology of the human β 3-adrenoceptor expressed in CHO cells and determine 1) the pharmacology of a range of "β-blockers" 2) examine antagonist affinity measurements and 3) look for This article has not been copyedited and formatted. The final version may differ from this version. C-cAMP recovery as previously described (Donaldson et al., 1988) .
This article has not been copyedited and formatted. The final version may differ from this version. 
and expressed as fmol/mg protein after protein was determined by the method of Lowry et al., (1951) .
One-site concentration responses curves
Sigmoidal agonist concentration-response curves were fitted using the following equation through computer-assisted non-linear regression using the programme Graphpad Prism 2:
where DR (dose ratio) is the ratio of the agonist concentration required to stimulate an identical response in the presence and absence of a fixed concentration of antagonist
.
In experiments where 3 to 6 different fixed concentrations of the same antagonist were used, Schild plots were constructed using the following equation:
These points were then fitted to a straight line. A slope of 1 then indicates competitive antagonism (Arunlakshana and Schild, 1959) .
Two site agonist curves
Concentration-response curves for ZD 7114 ( Figure 7 ) were fitted to two sites with Prism 2 using the equation:
where N is the percentage of site 1, [A] is the concentration of agonist and EC1 50 and EC2 50 are the respective EC 50 values for the two agonist sites.
A two-site analysis was also used for the experiments shown in Figures 6 and 8 using the following equation:
where basal is the response in the absence of agonist, Ag is the response to a fixed concentration of agonist, [P] is the concentration of partial agonist (e.g. alprenolol), IC 50 is the concentration of competing partial agonist that inhibits 50% of the response of the fixed agonist, PAg is the maximum stimulation by the competing partial agonist and EC 50 is the concentration of competing agonist that stimulated a half maximal competing partial agonist response.
A 10µM (maximal) isoprenaline concentration was included in each plate for each separate experiment for CRE-luciferase and
Results

Expression level of human β 3-adrenoceptors in CHO-β3 cells
In CHO-β3 cells, the log K D value for CGP 12177 was -6.65 ± 0.07 (n=8) and the receptor expression level 677 ± 89 fmol/mg protein (n=8).
Identification of agonists, partial agonists and neutral antagonists
In order to investigate changes in antagonist affinity measurements, full and partial agonists and neutral antagonists of the human β 3-adrenoceptor were required. Using CHO-β3-luciferase cells, six or seven point concentration responses (to a maximum of 100µM) were therefore constructed with a range of ligands and both CREluciferase production and 3 H-cAMP accumulation were measured. Several ligands did not stimulate any change in either 3 H-cAMP accumulation or CRE-luciferase production (n=3 for each ligand in each assay, Figure 1a , Table 1 ). Other ligands stimulated an increase in both 3 H-cAMP accumulation and CRE-luciferase production at high concentrations however the top of the concentration response was not reached with 100µM ligand in each case (n=3 for each ligand in each assay, Figure 1b , Table   1 ). Several agonists were identified (see Table 1 ). Of those ligands with no intrinsic activity, ICI 118551 had one of the highest affinities (Baker 2005b ) and was therefore used as the main neutral antagonist in further studies.
Antagonist affinity measurements -CRE-luciferase production
Isoprenaline stimulated an increase in CRE-luciferase production that was 8.5 ± 0.5 fold over basal (log EC 50 = -7.48 ± 0.05, n=15, Figure 2 ). These responses were inhibited by several antagonists to give log K D values as shown in Table 2 . However, when the ability of antagonists to inhibit other agonists were examined, the responses to some agonists (e.g. fenoterol) were more readily inhibited, and others (e.g. CGP 12177) more resistant to antagonism than the catecholamines (Table 2 , Figures 2-4).
In order to investigate this further, the ability of three of the antagonists to inhibit a larger range of agonists was studied (Table 3) . A range of antagonist affinities can clearly be seen with some agonists more resistant to antagonism than CGP 12177.
In order to determine whether the agonist responses were competitively inhibited, fenoterol, BRL 37344, isoprenaline and CGP 12177 responses were inhibited by 6
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Evidence for two agonist-conformations of the β 3-adrenoceptor
The range of antagonist affinity values is similar to that seen at the β 1-adrenoceptor which is now regarded to have two-agonist states. In order to determine whether ligands can act as neutral antagonists of a putative β 3-high-affinity state whilst being agonists of a low-affinity conformation of the β3-adrenoceptor (as seen at the β1-adrenoceptor), alprenolol (partial agonist, bottom of Table 3 ) was added to cells simultaneously with a fixed concentration of fenoterol (top of Table 3, Figure 6a ) in a manner analogous to that in β 1-adrenoceptor experiments (Pak and Fishman 1996; Konkar et al., 2000; Baker et al., 2003a; Baker, 2005a) . Alprenolol was found to inhibit the maximum response stimulated by fenoterol at concentrations 10-fold lower than that required to stimulate its agonist response (i.e. inhibitory component to the left of the EC 50 for alprenolol, n=4, Figure 6a ). A similar pattern was seen with SR 59230A (Figure 6b, n=4) .
Two-site agonist responses.
When ZD 7114 was examined as an agonist (CRE-luciferase production), the concentration response observed best fits to a 2-component response (log EC 50 1 = -7.30 ± 0.03, 68.5 ± 1.6% of the total response; log EC 50 2 = -4.78 ± 0.06; n=18, This article has not been copyedited and formatted. The final version may differ from this version. In order to investigate the human β 3-adrenoceptor, full and partial agonists and neutral antagonists were identified. Many of those identified were in agreement with previous studies (Blin et al., 1993) . As seen with β 1 and β 2-adrenoceptors, several ligands usually considered as β -antagonists had β 3-adrenoceptor agonist activity (Table 1 ) again in agreement with previous studies (Blin et al., 1993; Gerhardt et al., 1999; Hutchinson et al., 2005) . Also as seen in previous CRE-gene transcription studies (e.g. Baker et al., 2004) , the efficacy of partial agonists appeared greater in downstream CRE-gene transcription than at the second messenger level ( 3 H-cAMP; Table 1 ). No ligands were found to have inverse agonist activity in either assay in this CHO-human-β3 cell line.
The endogenous catecholamines adrenaline and noradrenaline stimulated full agonist responses similar to that of isoprenaline (see Table 1 ). When these responses were antagonised by ligands with no or minimal intrinsic efficacy, the antagonist affinities obtained were very similar, suggesting that the three catecholamines were binding to and activating the receptor in a similar manner (Table 2) . However, when this was extended to several other full-agonists, the antagonist affinity measurements differed.
Some agonist responses e.g. fenoterol and cimaterol were more readily inhibited than the catecholamines by all antagonists. CGP 12177 responses were more resistant to inhibition (Table 2) . This is very similar to findings at human β 1-adrenoceptors expressed in CHO-cells (Baker 2005a ).
This article has not been copyedited and formatted. The final version may differ from this version. To investigate this further, a wider range of agonists, including partial agonists, were inhibited by three antagonists, ICI 118551 (no intrinsic efficacy, higher affinity), betaxolol (no intrinsic efficacy, lower affinity) and timolol (minimal agonist efficacy, higher affinity). For all three antagonists, the affinity measurements obtained depended on the agonist present. As the only difference between each experiment was the agonist, this suggests that the agonists themselves were responsible for inducing different receptor conformations to which the antagonists could either bind with high-affinity (e.g. in the presence of fenoterol, top of Table 3 ) or low-affinity (e.g. in the presence of alprenolol, bottom of Table 3 ).
Changing antagonist affinity occurs at both β 1 and β 2-adrenoceptors. With β 2-adrenoceptors, antagonist affinity measurements were the same in short-term cAMP assays however in longer-term assays (cAMP and CRE-gene transcription), efficacious agonists caused an efficacy-driven change in the receptor that reduced antagonist affinity by ten-fold (Baker et al., 2003c) . As antagonist affinity measurements differed at the β 3-adrenoceptor in this CRE-gene transcription study,
shorter-term β 3-adrenoceptor cAMP responses were therefore examined. The log K D values for ICI 118551 in the cAMP assays were very similar to those obtained in long-term gene transcription assay (Table 3 ). There is therefore no time-dependent change in antagonist affinity. Also the efficacy of the competing agonists was unrelated to the antagonist affinity value obtained (see Tables 1 and 3 This article has not been copyedited and formatted. The final version may differ from this version. Firstly, all catecholamines induce full agonist responses at both receptors that are inhibited to yield mid-range antagonist affinity measurements at each receptor.
Secondly, at both receptors, at one end of the spectrum (top of Table 3 Table 3 are acting through a "high-affinity" state and those at the bottom of Table 3 via a "low-affinity" state of the β 3-adrenoceptor. Agonists in the middle of Table 3 may therefore be acting through both putative states of the β 3-adrenoceptor. Thirdly, whilst the rank order of antagonist affinities for high-affinity-state agonists is the same as for the catecholamines in both β 1 and β 3-adrenoceptors, it is different for low-affinity state ligands (Figure 4 ; Baker 2005a). The identical rank order for the high-affinity-state ligands suggest that these ligands may be acting through a different conformation of the same receptor rather than a truly different third state, whilst the low-affinity ligands are indeed acting via a truly different state of the two receptors.
There are however some differences from previous β 1-adrenoceptor findings. Firstly, differences in antagonist affinity for the β 1-adrenoceptor vary by 30 and 1000-fold depending on the antagonist (Joseph et al., 2004; Baker et al., 2005a) . In this β 3-adrenoceptor study, although significant, antagonist affinity measurements vary by only 4-50 fold (Tables 2 and 3) . Secondly, the correlation between antagonist affinity at the β 1-high-affinity-state and β 1-low-affinity-state is very poor (Baker 2005a) suggesting two very different receptor states or conformations. In this β 3-adrenoceptor study, the correlation of antagonist affinities at the high and low affinity-states (Figure 4 ) is again not as marked as that seen at β 1-adrenoceptors.
However, given the similarities to β 1-adrenoceptors, evidence of a potential secondary β 3-adrenoceptor state was sought.
In order to determine whether fenoterol (top of to the right of EC 50 ). However, alprenolol inhibited the stimulation of fenoterol at lower concentrations (i.e. to the left) of those expected ( Figure 6 ). This strongly suggests that the agonist effects of alprenolol and fenoterol are not competing at the same conformation. Similar results are seen with SR 59230A (Figure 6 ). This suggests that (as with CGP 12177 and the β 1-adrenoceptor), alprenolol is acting as a high-affinity-state neutral antagonist whilst stimulating agonist responses at higher concentrations via a low-affinity-state of the β 3-adrenoceptor.
ZD 7114 stimulated a response that was best described by a 2-component fit ( Figure   7 ). As this response was seen at both 3 H-cAMP accumulation and CRE-gene transcription, it suggests β 3-Gs-coupling only. The first component of the ZD 7114 response was more readily antagonised than the second, which is very reminiscent of alprenolol and pindolol responses at β 1-adrenoceptors (Baker et al., 2003a Correlation between antagonist log K D values with isoprenaline as agonist (x-axis) versus those obtained with agonists in Table 2 and alprenolol and SR 59230A from This article has not been copyedited and formatted. The final version may differ from this version. , betaxolol, bisoprolol, bupranolol, CGP 20712A, ICI 118551, metoprolol, practolol, sotalol H-cAMP accumulation and CRE-luciferase production experiments) and timolol and betaxolol (determined in CRE-luciferase experiments) in the presence of a range of agonists. Values are mean ± s.e.m. of n determinations. N.D. = not determined. *** = p < 0.001; ** = p < 0.01; * = p < 0.05 when comparing the log K D value of the antagonist with that obtained in the presence of isoprenaline (one-way analysis of variance (ANOVA), Neuman-Keul's post hoc). This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version.
